This is the authors' abstract. We don't add key points for this paper.
Background and objectives Photodynamic treatment with methylene blue (MB) and visible light is a well‐established pathogen inactivation system for human plasma. This technique is routinely used in different countries. MB/light treatment was shown to inactivate several transfusion‐transmittable viruses, but its efficiency for the inactivation of the quasi‐enveloped hepatitis E virus (HEV) has not yet been investigated. Materials and methods Plasma units were spiked with cell culture‐derived HEV and treated with the THERAFLEX MB‐Plasma system using various light doses (30, 60, 90, and 120 J/cm2). HEV titers in pre‐ and post‐treatment samples were determined by virus titration and a large‐volume plating assay to improve the detection limit of the virus assay. Results THERAFLEX MB‐Plasma efficiently inactivated HEV in human plasma. Even the lowest light dose of 30 J/cm2 inactivated HEV down to the limit of detection, with a mean log reduction factor of greater than 2.4 for the total process. Conclusion Our study demonstrates that the THERAFLEX MB‐Plasma system effectively inactivates HEV in human plasma.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Gravemann et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: